



ISSN 2349-7750

**INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES**Available online at: <http://www.iajps.com>

Research Article

SYNTHESIS AND BIOLOGICAL EVALUATION OF (3S)-3-[4-METHOXYMETHOXY) BENZYL] MORPHOLINE DERIVATIVES FROM L-TYROSINE**Loganathan Velupillai¹, Prashant P Dixit², M. S. Shingare¹, D. V. Mane*¹.**

1. Department of Chemistry, Dr. Babasaheb Ambedkar Marathwada University, Aurangabad, Maharashtra, India- 431004.

2. Department of Microbiology, Dr. Babasaheb Ambedkar Marathwada University, Aurangabad, Sub campus, Osmanabad, Maharashtra, India- 413501.

Abstract:

Morpholine backbone is essential in different pharmacologically active synthetic compounds. Present work is synthesis of novel morpholine nucleus based compounds such as (3S)-3-[4-(methoxymethoxy) benzyl] morpholine and their derivatives (3 I – 3 O). The compounds were synthesized in multistep reaction with more efficient process starting from L-Tyrosine as key starting material. The moiety L-Tyrosine is commercially available and is also available from Sigma-Aldrich. The chemical structures of the synthesized compounds were confirmed by means of ¹HNMR and mass spectral data. High yield and high purity indicates lack of side reaction and by product. The synthesized compounds were then examined for their antibacterial and antifungal activities. Some of them were found to possess good antibacterial and antifungal activity.

Keywords: Morpholine, Tyrosine, Antibacterial, Antifungal Activity.

Corresponding Author:

Loganathan Velupillai,

Department of Chemistry,

Dr. Babasaheb Ambedkar Marathwada University,

Aurangabad, Maharashtra, India- 431004

Email: dymane11@gmail.com vloganathan007@gmail.com

Please cite this article in press as Loganathan et al. **Synthesis and Biological Evaluation of (3s)-3-[4-Methoxymethoxy) Benzyl] Morpholine Derivatives from L-Tyrosine**, *Indo American J of Pharm Sci* 2015;2(3):722-730.

INTRODUCTION

Though there are many of active compounds developed for functionalized morpholine. Still there is scope for synthesis of new compounds to built morpholine ring system & it found to be among the most efficient for achieving useful transformations in to morpholine backbone and their derivatives later on. Nitrogen and oxygen containing heterocyclic compounds like morpholine [1] and substituted morpholine [2-5] are very important building blocks in medicinal chemistry [6] field. So the morpholine derivatives are extensively very essential in the drug discovery research, which stimulate research activity in the field of the broad spectrum of biological activity [7] study. After the literature survey that many morpholine derivative molecule are shows very good biological activity in different therapeutic area

such as antibacterial [8], antiviral, anticancer, antimicrobial, antidiabetic, anti-Inflammatory, antimalarial, antifungal [9], Antiemetic etc.

Hence, in the present study, some new substituted morpholine like (3S)-3-[4-(methoxymethoxy) benzyl] morpholine and their derivatives have been synthesized. The prepared substituted morpholine and three derivatives are very useful building blocks in medicinal chemistry. After the preparation of derivatives, the deprotection of methoxy methyl (MOM) [10] group will give phenolic hydroxyl which is also very useful building blocks in drug discovery synthesis. The chemical structures of the synthesized compounds were confirmed by spectroscopic methods like ¹HNMR and mass spectral data.




Figure 1: Marketed drugs containing a direct linked morpholine ring.




Figure 2: Clinical and preclinical drugs having a fused morpholine ring.

MATERIALS AND METHODS

All the reagents and solvents were used as obtained from the supplier or recrystallized/redistilled as necessary. The moiety L-Tyrosine [11-15] is commercially available and is also in Sigma Aldrich. This can be also synthesized as per reported literature. Melting points were recorded on open capillary melting point apparatus and are uncorrected. Mass spectra were recorded on 'LCMS-QP2010s' instrument by direct injection method. Nuclear Magnetic Resonance spectra (^1H NMR) were recorded in DMSO-d_6 & CDCl_3 on Bruker advance spectrometer at 400MHz using Tetramethylsilane (TMS) as internal standard and the chemical shift (δ) are reported in parts per million. The purity of the synthesized compounds was checked by Thin Layer Chromatography, Merck pre-coated plates (silica gel 60 F254) were visualized with UV light. Fungus Culture: *Candida* sp. Gram-positive microorganisms: *Staphylococcus aureus*, *Staphylococcus albus*, *Streptococcus faecalis*, *Bacillus* sp and Gram-negative microorganisms: *Klebsiella pneumoniae*, *Escherichia coli*, *Pseudomonas* sp, *Proteus* sp were used for biological activity.

Antimicrobial Activity:

The antimicrobial activity of all synthesized compounds (3 I – 3 O) were screened against different standard organism obtained from the American type of cell culture collection, including *Staphylococcus aureus*, *Escherichia coli*

and *Pseudomonas* sp. Agar diffusion technique at the concentration level of $5\mu\text{g}$ molar was applied. Ciprofloxacin was used as reference compounds for antibacterial activities.

The antimicrobial activity of all the newly synthesized compounds were determined by well plate method in nutrient agar (Hi-media) was used for antibacterial activity. The antibacterial activity of the test compounds was assayed against gram-positive and gram-negative by Cup plate method. The compounds were tested at a concentration of a $100\mu\text{g}/\text{ml}$ were prepared in dimethylformamide (DMF). The Petri dishes used for antibacterial screening were incubated at 37 ± 1 for 24h; the diameters of zone of inhibition (mm) surroundings each of the wells recorded. The results were compared Ciprofloxacin of a $100\mu\text{g}/\text{ml}$ concentration (cacic, M *et al.*, 2006).

Antifungal Activity:

The antifungal activity of all synthesized compounds (3 I – 3 O) screened against *Candida* sp in DMF by poisoned food technique. Fluconazole was employed as standard drug during the test procedures as references. Potato dextrose agar (PDA) Media were prepared and about 15ml of PDA was poured into each Petri plate allowed to solidify 5mm disc of seven-day-old culture of the test fungi was placed at the centre of the Petri plates and incubated at 26°C for 7 days. After incubation, the percentage inhibition was measured and three replicates were maintained for each treatment.

EXPERIMENTAL











Fig 3: Synthesis of (3S)-3-[4-methoxymethoxy]benzyl] morpholine and their derivatives.

Table 1: Physical Data of Synthesized Compounds (3 I – 3 O).

Code	-R	Molecular Formula	M.wt	M.P (°C)	% Yield
3 I		C ₂₀ H ₃₀ N ₂ O ₄	362.4	67-69	83
3 J		C ₂₀ H ₂₄ N ₂ O ₄	356.4	73-74	80
3 K		C ₂₂ H ₂₇ NO ₅	385.4	55-57	87
3 L		C ₂₃ H ₂₉ NO ₄	383.4	79-81	92
3 M		C ₂₀ H ₂₃ NO ₄	341.4	47-49	80
3 N		C ₁₅ H ₂₀ N ₂ O ₃	276.3	36-37	78
3 O		C ₂₁ H ₂₅ NO ₄	355.4	44-46	86

Preparation of methyl (2S)-2-amino-3-(4-hydroxyphenyl) propionate Hydrochloride (A):

The thionylchloride (14.44g, 121mmol) was added to the solution of L-Tyrosine (20gm, 110mmol) in methanol (120ml) at 0°C and the mixture was stirred for 16 hr at room temperature. After completion of reaction, the solution was evaporated in vacuum and residue was suspended in 200ml acetone, stirred for 30 mins. Filtered and dried. Yielded the titled product (A) as white solid.

Preparation of Methyl (2S)-2-[[Benzyloxy]carbonyl]amino]-3-(4-hydroxyphenyl) propanoate (B):

The Benzyl chloroformate (19.22g, 112mmol) was added to the solution of compound (A) (20gm, 102mmol), sodium bicarbonate (17.21g, 204mmol) in water (120ml) at 10°C and the mixture was stirred for 2hr at room

temperature. After completion of reaction, the reaction mass extracted with twice with 100ml of ethyl acetate, dried with sodium sulfate and distilled out completely. The crude was suspended in n-Hexane (200ml) and the suspension was stirred at room temperature for 1hr. Filtered and washed with n-Hexane (40ml), after drying yielded the titled product (B) as white solid.

Preparation of Methyl (2S)-2-[[Benzyloxy]carbonyl]amino]-3-[4-(methoxymethoxy)phenyl]propanoate (C):

The chloromethyl methyl ether (5.28g, 65mmol) was added to the solution of compound (B) (18gm, 54mmol), N,N-Diisopropyl ethylamine (14.12g, 109mmol) in dichloromethane (108ml) at 0°C and the mixture was stirred for overnight at room temperature. After completion of reaction, the

solution was evaporated in vacuum and the residue was suspended in 180ml of ethyl acetate and washed with 2×100 of water. The organic layer dried with sodium sulfate and distilled out completely. Yielded the titled product (C) as oily mass.

Preparation of benzyl{ (2S)-1-hydroxy-3-[4-(methoxymethoxy)phenyl]propan-2-yl} carbamate (D):

The compound (C) (15g, 40mmol) in 50ml of tetrahydrofuran was added slowly to the solution of lithium borohydride (1.3gm, 60mmol) in tetrahydrofuran (100ml) at 0°C and the mixture was stirred for 5hr at 0°C. After completion of reaction, the reaction was quenched with wet sodium sulfate. The reaction mass filtered through celite bed washed with tetrahydrofuran (15ml). The filtrate was distilled out completely. Yielded the titled product (D) as white solid.

Preparation of (2S)-2-amino-3-[4-(methoxymethoxy) phenyl] propan-1-ol (E):

The methanol (80ml), compound (D) (10g, 28mmol) and Pd-C (1gm) catalyst was added into the hydrogenation Parr-shaker reactor. 30 PSI of hydrogen gas applied and the mixture was shaken for 5hr. After completion of reaction, the reaction mass filtered through celite bed washed with methanol 20ml. The filtrate was distilled out completely. Yielded the titled product (E) as white solid.

Preparation of 2-chloro-N-{(2S)- 1-hydroxy-3-[4-(methoxymethoxy)phenyl]propan-2-yl} acetamide (F):

The chloroacetyl chloride (4.49g, 39mmol) was added to the solution of compound (E) (8gm, 37mmol), sodium bicarbonate (84g, 41mmol) in tetrahydrofuran (64ml) at 0°C and the mixture was stirred for 1hr at 0°C. After completion of reaction, the reaction filtered and removed the sodium bicarbonate. The filtrate concentrated completely. The crude was suspended in n-Hexane (80ml) and the suspension was stirred at room temperature for 1hr. Filtered and washed with n-Hexane (20ml), after drying yielded the titled product (F) as light brown solid.

Preparation of (5S)-5-[4-(methoxymethoxy) benzyl] morpholin-3-one (G):

The potassium tert-butoxide (2.63gm, 23mmol) was added to the solution of compound (F) (4.5gm, 15mmol) in N,N-Dimethylformamide (45ml) and the mixture was stirred for 5hr at room temperature. After completion of reaction, the reaction mass poured into cold water (200ml). The reaction mass pH was neutralized with 5% AcOH solution. The reaction mass was stirred at room temperature for

3hr. Filtered and washed with water (20ml), after drying yielded the titled product (G) as white solid.

Preparation of (3S)-3-[4-(methoxymethoxy) benzyl] morpholine (H):

The compound (G) (3gm, 11mmol), in 15ml of tetrahydrofuran was added slowly to the solution of lithium aluminium hydride (0.68g, 17mmol) in tetrahydrofuran (15ml) at 0°C and the mixture was stirred for 4hr at room temperature. After completion of reaction, the reaction was quenched with wet sodium sulfate. The reaction mass filtered through celite bed washed with tetrahydrofuran 15ml. The filtrate was distilled out completely. Yielded the titled product (H) as oily mass.

Preparation of (3S)-3-[4-(methoxymethoxy) benzyl]-N-cyclohexylmorpholine-4-carboxamide (3 I):

The cyclohexyl isocyanate (0.42g, 3 mmol) was added to the solution of compound (H) (0.8gm, 3mmol) in tetrahydrofuran (8ml) at 0°C and the mixture was stirred for 1hr at 0°C. After completion of reaction, the reaction mass evaporated in vacuum and the residue was suspended in ethyl acetate (8ml) and washed with 2×4ml of water. The organic layer dried with sodium sulfate and distilled out completely. The crude was suspended in n-pentane (8ml) and the suspension was stirred at room temperature for 1hr. Filtered and washed with n-pentane (2ml), after drying yielded the titled product (3I) as white solid.

Preparation of (3S)-3-(4-methoxymethoxy)benzyl-N-phenylmorpholine-4-carboxamide (3 J):

The phenyl isocyanate (0.35g, 3 mmol) was added to the solution of compound (H) (0.7gm, 3mmol) in tetrahydrofuran (7ml) at 0°C and the mixture was stirred for 1hr 0°C. After completion of reaction, the reaction mass evaporated in vacuum and the residue was suspended in ethyl acetate (7ml) and washed with 2×3ml of water. The organic layer dried with sodium sulfate and distilled out completely. The crude was suspended in n-pentane (7ml) and the suspension was stirred at room temperature for 1hr. Filtered and washed with n-pentane (2ml), after drying yielded the titled product (3J) as white solid.

Preparation of benzyl [(3S)-3-(4-methoxymethoxy) benzyl] morpholine-4-acetate (3 K):

The benzyl bromoacetate (0.7g, 3mmol) was added to the solution of compound (H) (0.7gm, 3mmol) and cesium carbonate (1gm, 3mmol) in acetonitrile (7ml) and the mixture was stirred for 3hr at room temperature. After completion of reaction, the reaction mass evaporated in vacuum and the residue was suspended in ethyl acetate (7ml) and washed with 2×4ml of water. The organic layer dried with

sodium sulfate and distilled out completely. The crude was suspended in n-pentane (7ml) and the suspension was stirred at room temperature for 1hr. Filtered and washed with n-pentane (2ml), after drying yielded the titled product (3K) as white solid.

Preparation of (3S)-3-[4-methoxymethoxybenzyl] morpholine-4-phenylbutan-1-one (3 L):

The 4-phenylbutanoyl chloride (0.54g, 3mmol) was added to the solution of compound (H) (0.7gm, 3mmol) and cesium carbonate (1gm, 3mmol) in acetonitrile (7ml) and the mixture was stirred for 3hr at room temperature. After completion of reaction, the reaction mass evaporated in vacuum and the residue was suspended in ethyl acetate (7ml) and washed with 2×4ml of water. The organic layer dried with sodium sulfate and distilled out completely. The crude was suspended in n-pentane (7ml) and the suspension was stirred at room temperature for 1hr. Filtered and washed with n-pentane (2ml), after drying yielded the titled product (3L) as white solid.

Preparation of {(3S)-3-[4-(methoxymethoxy)benzyl] morpholin-4-yl}(phenyl)methanone (3 M):

The benzoyl chloride (0.41g, 3mmol) was added to the solution of compound (H) (0.7gm, 3mmol) and cesium carbonate (1gm, 3mmol) in acetonitrile (7ml) and the mixture was stirred for 3hr at room temperature. After completion of reaction, the reaction mass evaporated in vacuum and the residue was suspended in ethyl acetate (7ml) and washed with 2×4ml of water. The organic layer dried with sodium sulfate and distilled out completely. The crude was suspended in n-pentane (7ml) and the suspension was stirred at room temperature for 1hr. Filtered and washed with n-pentane (2ml), after drying yielded the titled product (3M) as white solid.

Preparation of {(3S)-3-[4-(methoxymethoxy)benzyl] morpholin-4-yl}acetonitrile (3 N):

The bromoacetonitrile (0.35g, 3mmol) was added to the solution of compound (H) (0.7gm, 3mmol) and cesium carbonate (1gm, 3mmol) in acetonitrile (7ml) and the mixture was stirred for 3hr at room temperature. After completion of reaction, the reaction mass evaporated in vacuum and the residue was suspended in ethyl acetate (7ml) and washed with 2×4ml of water. The organic layer dried with sodium sulfate and distilled out completely. The crude was suspended in n-pentane (7ml) and the suspension was stirred at room temperature for 1hr. Filtered and washed with n-pentane (2ml), after drying yielded the titled product (3N) as white solid.

Preparation of 2-[(3S)-3-[4-(methoxymethoxy)benzyl]morpholin-1-phenylethanone (3 O):

The phenacyl Bromide (0.58g, 3mmol) was added to the solution of

compound (H) (0.7gm, 3mmol) and cesium carbonate (1gm, 3mmol) in acetonitrile (7ml) and the mixture was stirred for 3hr at room temperature. After completion of reaction, the reaction mass evaporated in vacuum and the residue was suspended in ethyl acetate (7ml) and washed with 2×4ml of water. The organic layer dried with sodium sulfate and distilled out completely. The crude was suspended in n-pentane (7ml) and the suspension was stirred at room temperature for 1hr. Filtered and washed with n-pentane (2ml), after drying yielded the titled product (3O) as white solid.

RESULTS AND DISCUSSION

The results are obtained from various spectral data are results discussed below.

Preparation of methyl (2S)-2-amino-3-(4-hydroxyphenyl) propionate Hydrochloride (A): A white solid 22g (yield 88%). M.W: 231.6; Mol. For: C₁₀H₁₄ClNO₃; LC-MS (m/z): 196.1 (M+1, without HCl); ¹HNMR (400MHz, DMSOD₆): δ 9.44 (s, 1H), 8.52 (s, 2H), 6.99-7.01 (d, 2H), 6.70-6.73 (d, 2H), 4.16-4.19 (t, 1H), 3.67 (s, 3H), 2.98-3.03 (m, 2H).

Preparation of Methyl (2S)-2-[(Benzoyloxy)carbonyl]amino-3-(4-hydroxyphenyl) propanoate (B):

A white solid 32g (yield 95%). M.W: 329.3; Mol. For: C₁₈H₁₉NO₅; LC-MS (m/z): 330.2 (M+1); ¹HNMR (400MHz, DMSOD₆): δ 9.23 (s, 1H), 7.76-7.78 (d, 1H), 7.25-7.37 (m, 5H), 7.00-7.02 (d, 2H), 6.64-6.66 (d, 2H), 4.98 (s, 2H), 4.15-4.18 (m, 1H), 3.61 (s, 3H), 2.88-2.91 (m, 1H), 2.73-2.77 (m, 1H).

Preparation of Methyl (2S)-2-[(benzyloxy)carbonyl]amino-3-[4-(methoxymethoxy)phenyl]propanoate (C):

An oily mass 16g (yield 80%). M.W: 373.3; Mol. For: C₂₀H₂₃NO₆; LC-MS (m/z): 374.3 (M+1); ¹HNMR (400MHz, DMSOD₆): δ 7.79-7.81 (d, 1H), 7.26-7.36 (m, 5H), 7.14-7.16 (d, 2H), 6.91-6.93 (d, 2H), 5.14 (s, 2H), 4.98 (s, 2H), 4.19-4.20 (m, 1H), 3.62 (s, 3H), 3.36 (s, 3H), 2.94-2.98 (m, 1H), 2.8-2.82 (m, 1H).

Preparation of benzyl{(2S)-1-hydroxy-3-[4-(methoxymethoxy)phenyl]propan-2-yl} carbamate (D):

A white solid 13g (yield 92%). M.W: 345.3; Mol. For: C₁₉H₂₃NO₅; LC-MS (m/z): 346.3 (M+1); ¹HNMR (400MHz, DMSOD₆): δ 7.10-7.35 (m, 8H), 6.90-6.92 (d, 2H), 5.14 (s, 2H), 4.94 (s, 2H), 4.73-4.76 (t, 1H), 3.59-3.60 (m, 1H), 3.36 (s, 3H), 3.27-3.31 (m, 1H), 2.75-2.80 (m, 1H).

Preparation of (2S)-2-amino-3-[4-(methoxymethoxy)phenyl]propan-1-ol (E):

A white solid 5g (yield 83%). M.W: 211.2; Mol. For: C₁₁H₁₇NO₃; LC-MS (m/z): 212.2 (M+1); ¹HNMR

(400MHz, DMSOD₆): δ 7.10-7.12 (d, 2H), 6.91-6.93 (d, 2H), 5.14 (s, 2H), 4.60 (s, 1H), 3.25-3.29 (m, 2H), 3.14-3.18 (m, 2H), 2.80-2.84 (m, 1H), 2.58-2.63 (m, 1H), 2.34-2.39 (m, 2H), 1.90 (bs, 2H).

Preparation of 2-chloro-N-((2S)-1-hydroxy-3-[4-(methoxymethoxy)phenyl]propan-2-yl)acetamide (F): A brown solid 10g (yield 95%). M.W: 287.7; Mol. For: C₁₃H₁₈ClNO₄; LC-MS (m/z): 288.2 (M+1); ¹HNMR (400MHz, DMSOD₆): δ 8.04-8.06 (d, 1H), 7.10-7.12 (d, 2H), 6.90-6.92 (d, 2H), 5.14 (s, 2H), 4.83 (s, 1H), 4.00 (s, 2H), 3.83-3.85 (1H), 3.35 (s, 3H), 2.74-2.79 (m, 1H), 2.56-2.62 (m, 1H).

Preparation of (5S)-5-[4-(methoxymethoxy)benzyl]morpholin-3-one (G): A white solid 3.7g (yield 96%). M.W: 251.2; Mol. For: C₁₃H₁₇NO₄; LC-MS (m/z): 252.2 (M+1); ¹HNMR (400MHz, DMSOD₆): δ 8.10 (s, 1H), 7.11-7.13 (d, 2H), 6.94-6.96 (d, 2H), 5.15 (s, 2H), 3.93 (s, 2H), 3.53-3.61 (m, 2H), 3.38-3.41 (m, 1H), 3.36 (s, 3H), 2.67-2.82 (m, 1H), 2.62-2.67 (m, 1H).

Preparation of (3S)-3-[4-(methoxymethoxy)benzyl]morpholine (H): A oily mass 2.7g (yield 96%). M.W: 237.2; Mol. For: C₁₃H₁₉NO₃; LC-MS (m/z): 238.1 (M+1); ¹HNMR (400MHz, DMSOD₆): δ 7.09-7.11 (d, 2H), 6.92-6.94 (d, 2H), 5.14 (s, 2H), 3.54-3.62 (m, 2H), 3.27-3.33 (m, 2H), 3.00-3.05 (t, 1H), 2.65-2.77 (m, 3H), 2.18-2.44 (t, 2H), 1.35 (s, 1H).

Preparation of (3S)-3-[4-(methoxymethoxy)benzyl]-N-cyclohexylmorpholine-4-carboxamide (3 D): A white solid 1g (Yield 83%). M.W: 362.4; Mol. For: C₂₀H₃₀N₂O₄; LC-MS (m/z): 363.3 (M+1); ¹HNMR (400MHz, DMSOD₆): δ 7.10-7.12 (d, 2H), 6.92-6.94 (d, 2H), 5.99-6.01 (d, 1H), 5.14 (s, 2H), 3.97 (s, 1H), 3.80-3.83 (d, 1H), 3.50-3.59 (m, 2H), 3.35 (s, 3H), 3.06-3.09 (m, 2H), 2.84-2.90 (m, 1H), 2.60-2.66 (m, 1H), 1.53-1.71 (m, 4H), 1.03-1.22 (m, 4H).

Preparation of (3S)-3-(4-methoxymethoxy)benzyl-N-phenylmorpholine-4-carboxamide (3 J): A white solid 0.8g (Yield 80%). M.W: 356.4; Mol. For: C₂₀H₂₄N₂O₄; LC-MS (m/z): 357.3(M+1); ¹HNMR (400MHz, DMSOD₆): δ 8.35 (s, 1H), 7.13-7.34 (m, 7H), 6.90-6.93 (d, 2H), 5.09 (s, 2H), 4.21 (s, 1H), 3.88-3.91 (d, 1H), 3.75-3.78 (d, 1H), 3.60-3.63 (d, 1H), 3.37-3.43 (m, 2H), 3.25-3.29 (m, 1H), 2.92-2.96 (m, 1H), 2.80-2.81 (m, 2H).

Preparation of benzyl [(3S)-3-(4-methoxymethoxy)benzyl]morpholine-4-acetate (3 K): A white solid 1g (Yield 88%). M.W: 385.4; Mol. For: C₂₂H₂₇NO₅; LC-MS (m/z): 386.4 (M+1); ¹HNMR (400MHz, DMSOD₆): δ 7.30-7.39 (m, 5H), 6.99-7.02 (d, 2H),

6.88-6.92 (d, 2H), 5.18 (s, 2H), 4.27-4.29 (d, 1H), 3.88-3.90 (d, 1H), 3.57-3.61 (m, 1H), 3.35 (s, 3H), 3.32 (s, 2H), 3.04-3.08 (t, 1H), 2.66-2.82 (m, 2H), 2.30-2.38 (m, 2H).

Preparation of (3S)-3-[(4-methoxymethoxy)benzyl]morpholine-4-phenylbutan-1-one (3 L): A white solid 710mg (yield 63%). M.W: 383.4; Mol. For: C₂₃H₂₉NO₄; LC-MS (m/z): 384.3(M+1); ¹HNMR (400MHz, DMSOD₆): δ 7.03-7.28 (m, 7H), 6.90-6.93 (d, 2H), 5.14 (s, 2H), 4.15-4.18 (d, 1H), 3.81-3.88 (d, 2H), 3.60-3.69 (m, 2H), 3.36 (s, 3H), 3.06-3.09 (m, 1H), 2.90-2.94 (m, 2H), 2.67-2.71 (m, 2H), 2.13-2.18 (t, 2H), 1.57-1.68 (m, 2H).

Preparation of {(3S)-3-[4-(methoxymethoxy)benzyl]morpholin-4-yl}(phenyl)methanone (3 M): A white solid 810mg (Yield 80%). M.W: 341.4; Mol. For: C₂₀H₂₃NO₄; LC-MS (m/z): 342.3 (M+1); ¹HNMR (400MHz, DMSOD₆): δ 7.48-7.66 (m, 5H), 7.10-7.13 (d, 2H), 6.87-6.90 (d, 2H), 5.15 (s, 2H), 4.23-4.27 (d, 1H), 3.97-4.01 (d, 1H), 3.36 (s, 3H), 3.20-3.25 (m, 1H), 2.91-2.96 (m, 2H), 2.67-2.83 (m, 2H).

Preparation of {(3S)-3-[4-(methoxymethoxy)benzyl]morpholin-4-yl}acetonitrile (3 N): A white solid 0.5mg (yield 62%). M.W: 276.3; Mol. For: C₁₅H₂₀N₂O₃; LC-MS (m/z): 277.3 (M+1); ¹HNMR (400MHz, DMSOD₆): δ 7.09-7.11 (d, 2H), 6.94-6.96 (d, 2H), 5.15 (s, 2H), 3.83-4.21 (d, 1H), 3.70-3.83 (m, 2H), 3.42-3.49 (m, 2H), 3.36 (s, 3H), 3.10 (t, 1H), 2.94-2.98 (m, 1H), 2.70-2.93 (d, 1H), 2.43-2.48 (m, 2H), 2.27-2.33 (m, 1H).

Preparation of 2-[(3S)-3-[4-(methoxymethoxy)benzyl]morpholin-1-phenylethanone (3 O): A white solid 0.59mg (yield 57%). M.W: 355.4; Mol. For: C₂₁H₂₅NO₄; LC-MS (m/z): 356.3(M+1); ¹HNMR (400MHz, DMSOD₆): δ 7.48-7.65 (m, 5H), 7.10-7.13 (d, 2H), 6.87-6.90 (d, 2H), 5.13 (s, 2H), 4.24-4.28 (d, 1H), 3.97-4.01 (d, 1H), 3.51-3.74 (m, 4H), 3.35 (s, 3H), 3.20-3.25 (m, 1H), 2.91-2.96 (m, 2H), 2.67-2.83 (m, 2H).

Biological Evaluation

Some of the synthesized compounds showed good antimicrobial activity inhibition. Antimicrobial screening results of the tested compounds are shown in Table 2. All the synthesized compounds showed moderate inhibitory activity and compound (3 L) showed good antifungal activity inhibition compared to other compound. Antifungal screening results of the tested compounds are shown in Table 2.

Table 2: Antibacterial and Antifungal activity data of compounds (3 I – 3 O).

Compound No.	Inhibition Zone Diameter (mm)								
	I	II	III	IV	V	VI	VII	VIII	IX
3 I	10	19	21	11	19	11	10	20	22
3 J	12	17	18	10	10	13	13	19	21
3 K	13	29	26	22	13	25	19	23	24
3 L	17	20	21	10	12	12	12	13	17
3 M	09	26	27	16	19	10	15	19	19
3 N	11	29	25	18	20	13	18	16	20
3 O	12	30	28	20	16	29	19	29	28
Control (Solvent)	8	11	17	12	11	14	11	13	11
Ciprofloxacin	---	20	22	16	13	17	16	21	23
Fluconazole	14	---	---	---	---	---	---	---	---

Microbial Cultures Used to test antimicrobial Activity, *Fungus Culture*: I-Candida sp. *Gram Positive Bacteria*: II-Staphylococcus aureus, III-Staphylococcus albus, VIII-Streptococcus faecalis, IX- Bacillus sp. *Gram Negative Bacteria*: IV-Klebsiella pneumoniae, V-Escherichia coli, VI- Pseudomonas sp, VII- Proteus s.

CONCLUSION

In this study, the synthesis of some morpholine derivatives (3 I – 3 O) was performed and their structures were confirmed by ¹HNMR, Mass spectroscopy techniques. In addition, the newly synthesized compounds were screened for their antibacterial and antifungal activities. Some of them were found to possess good antibacterial and antifungal activity.

ACKNOWLEDGEMENTS

The authors are thankful to management of department of chemistry, Dr. Babasaheb Ambedkar Marthawada University, Aurangabad, Maharashtra, India for providing research facilities.

REFERENCES

1. Review of morpholine and its derivatives, Merck Index, 12th ed. published by Merck & Co, Whitehouse Station, NJ, 1996;1074-5.
2. Pushpak Mizar, Bekington Myrboth. Synthesis of substituted 4-(3-alkyl-1,2,4-oxadiazol-5-ylmethyl)-3,4-dihydro-2H-1,4-benzoxazines and 4-

(1H-benzimidazol-2-ylmethyl)-3,4-dihydro-2H-1,4-benzoxazines. Tetrahedron Letters. 2006; 47(44):7823-26.

3. Satoshi Sakami, Koji Kawai, Masayuki Maeda, Takumi Aoki, Hideaki Fujii, Hiroshi Ohno et al. Design and synthesis of a metabolically stable and potent antitussive agent, a novel δ opioid receptor antagonist, TRK-851. Bioorg Med Chem. 2008;16(17):7956-67.
4. Gang Zhou, Nicolas Zorn, Pauline Ting, Robert Aslanian, Mingxiang Lin, John Cook et al. Development of Novel Benzomorpholine Class of Diacylglycerol Acyltransferase I Inhibitors. Med Chem Lett. 2014;5(5):544-49.
5. Xianhai Huang, Dmitri Pissarnitski, Hongmei Li, Theodoros Asberom, Hubert Josien, Xiaohong Zhu et al. Efficient synthesis and reaction pathway studies of novel fused morpholine oxadiazolines for use as gamma secretase modulators. Tetrahedron Letters. 2012;53(47):6451-55.
6. Madhu Chopra, VK Ahluwalia. Ane's Student Edition, Text Book of Medicinal

Chemistry, 1st ed. New Delhi Published by Ane's Books Pvt. Ltd, 2008.

7. Basudeb Achari, Sukhendu BM, Pradeep Dutta, Chinmay Chowdhury. Perspectives on 1, 4-Benzodioxions, 1, 4-Benzoxazines and Their 2, 3-Dihydro Derivatives. *Synlett*. 2004; 14:2449-67.
8. Duhalde V, Lahillie B, camou F, Pedeboscq S, pometan JP. Proper use of antibiotics: a prospective study on the use of linezolid in a French university hospital. *Pathologie biologique*. 2007; 55(10):478-81.
9. K Marireau C, Guilloton M, kartst F. In vivo effects of fenpropimorph on the yeast *Saccharomyces cerevisiae* and determination of the molecular basis of the antifungal property. *Antimicrobial agents and chemotherapy*. 1990; 34(6):989-93.
10. T.W. Greene and P.G.M Green, *Protective Groups in Organic Synthesis*, 3rd Edition, published by John Wiley & Sons Inc, New York, 1999;27-33.
11. Ramesh N. Patel, Venkata Nanduri, David Brzozowski, Clyde McNamee, Amit Banerjee. Enantioselective Enzymatic Cleavage of N-Benzyloxycarbonyl Groups. *Advanced Synthesis & Catalysis*. Jun-2003; 830-34.
12. Alexander G Russell, Matthew J Sadler, Helen J Laidlaw, Agustín Gutiérrez-Loriente, Christopher W Wharton, David Carteau et al. Photorelease of tyrosine from α -carboxy-6-nitroveratryl (α CNV) derivatives. *Photochemical & photobiological Sciences*. 2012;11(3): 556-563.
13. Haruaki Yajima, Nobutaka Fujii, Susumu Funakoshi, Toshihiro Watanabe, Eigo Murayama, Akira Otake. New strategy for the chemical synthesis of proteins. *Tetrahedron*. 1988;44(3):805-19.
14. Andrey Galkin, Ljudmila Kulakova, Tohru Yoshimura, Kenji Soda, Nobuyoshi Esaki. Synthesis of Optically Active Amino Acids from α -Keto Acids with *Escherichia coli* Cells Expressing Heterologous Genes. *Applied and Environmental Microbiology*. 1997;63(12):4651-56.
15. Robert L Ory, Carl M Lyman. Synthesis of Tyrosine and Phenylalanine by *Lactobacillus arabinosus*. *J Bacteriology*. May 1955; 69(5):508–515.